Tale of Two Drugs: Wegovy Linked to Higher Risk of Blinding Eye Stroke vs Ozempic
(MedPage Today) — The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed.
In a…
FDA warns Novo Nordisk of potential unreported GLP-1 side effects
The FDA issued a warning letter to Novo Nordisk — the maker of Ozempic and Wegovy — for failing to report potential side effects in patients who took its blockbuster medications.
The Ultimate Grocery List for GLP-1 Users, According to a Dietitian
These kitchen staples are nutrient-dense and easy to tolerate.
FDA warns Novo Nordisk over unreported potential Ozempic side effects
The FDA issued a warning letter to Novo Nordisk, the Danish drugmaker behind the diabetes and weight-loss medications Ozempic and Wegovy, over unreported potential side effects.
GLP-1 Drugs and Osteoporosis; HbA1c at the Dentist? New Obesity Med Guide
(MedPage Today) — GLP-1 receptor agonists may increase the risk of bone and tendon injuries, as well as conditions like osteoporosis and gout, a retrospective study suggested. (Washington Post)
Chairside HbA1c testing during routine dental visits…
2018 to 2025 Saw Rise in GLP-1 Receptor Agonist Rx for Bariatric Surgery-Eligible Patients
TUESDAY, March 10, 2026 — Among patients eligible for metabolic and bariatric surgery (MBS), glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescriptions increased from 2018 to 2025, while MBS use decreased beginning in 2023, according to a…
Ascletis touts GLP-1 quarterly dosing data; Mineralys apnea Phase 2 misses
Plus, news about Telix Pharmaceuticals, Laekna, Prothena, Novo Nordisk, Keymed Biosciences, AstraZeneca and f5 Therapeutics:
📊 Ascletis trumpets potential quarterly dosing of GLP-1: An investigational subcutaneous depot formulation of Ascletis’s GLP-1 drug ASC30 …
STAT+: Novo Nordisk is warned by the FDA for failing to report side effects tied to GLP-1 drugs
It’s the third time in recent weeks that the FDA has admonished Novo Nordisk for different practices.
GLP-1s have transformed weight loss and diabetes. Is addiction next?
A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.
Can You Maintain Weight Loss With Fewer Injections of Ozempic, Wegovy?
A small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections. Image Credit: Siluk/UCG/Universal Images Group via Getty Images
A recent small study found that reduced GLP-1 frequency may help people maintain their weight loss.
The study shows that people who dosed as little as once every two months maintained weight loss and other improved health markers.